Robin 1987.

Methods	Study design: parallel‐group RCT Country: US Number randomized: Total: 73 Per group: apraclonidine = 39, placebo = 34 Exclusions after randomization: none reported Number analyzed: Total: 73 Per group: apraclonidine = 39, placebo = 34 Unit of analysis (participants vs eyes): participant (1 eye per participant); if a participant required bilateral therapy, the eye treated first was selected Losses to follow‐up: none reported How was missing data handled?: not reported Reported power calculation: no Unusual study design?: none
Participants	Age (mean ± SD; years): apraclonidine = 60.9 ± 14.3, placebo = 68.8 ± 12.4 Females: apraclonidine = 54%, placebo = 74% Inclusion criteria: pre‐existing OAG and poor IOP control despite maximum tolerated medical therapy Exclusion criteria: prior ALT Equivalence of baseline characteristics: no, "There was no statistically significant difference in any variable except for mean patient age, (P<0.25)"
Interventions	Intervention 1: topical 1% apraclonidine, 1 hour prior and immediately after 360° ALT Intervention 2: placebo, 1 hour prior and immediately after 360° ALT Length of follow‐up: Planned: 1 month Actual: 1 month
Outcomes	Primary outcomes: visual acuity, IOP, anterior segment inflammation Secondary outcome: heart rate Adverse events reported: authors reported that there were no adverse events Intervals at which outcomes assessed: 1, 2, 3 hours; 1 week; 1 month
Notes	Trial registration: not reported Funding sources: "This study was funded in part by a grant from Alcon Laboratories." Disclosures of interest: "Betty House is an employee of Alcon Laboratories, Fort Worth, Tex. None of the authors as any financial, commercial, or proprietary interest in ALO 2145 [apraclonidine]." Study period: not reported Reported subgroup analyses: no
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"A computer‐generated random‐number table was utilized, and the selected medication was masked to both the physician and the patient."
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not reported.
Masking of participants and personnel (performance bias)	Low risk	"A computer‐generated random‐number table was utilized, and the selected medication was masked to both the physician and the patient."
Masking of outcome assessment (detection bias)	Unclear risk	No information on efforts to mask the outcome assessors reported.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No mention of loss to follow‐up.
Selective reporting (reporting bias)	Unclear risk	Unclear whether there was selective outcome reporting.
Other bias	High risk	Study funded in part by Alcon Laboratories, who manufacture the study drug apraclonidine.